Biotech and Investing Glossary

FDA (Food and Drug Administration) — The U.S. regulatory agency responsible for evaluating the safety and efficacy of drugs, biologics, and medical devices before they reach the market. It reviews clinical trial data, inspects manufacturing facilities, and enforces labeling requirements. Example: A company submits a New Drug Application to the FDA upon successful completion of Phase III studies.

EMA (European Medicines Agency) — The European Union’s centralized body for the scientific evaluation of medicines. It grants marketing authorizations valid across all EU member states. Example: A biosimilar approved by the EMA can be sold in 27 countries without additional national approvals.

Phase I — The initial clinical trial in humans, typically enrolling 20–80 healthy volunteers. It primarily investigates safety, tolerability, and dosing range. Example: A Phase I study for an mRNA vaccine established a dose that provoked neutralizing antibodies without severe adverse events.

Phase II — A trial in 100–300 patients with the target disease, aimed at understanding efficacy and further characterizing safety. This stage often generates the first signal of clinical benefit. Example: A Phase II Alzheimer’s trial reported a statistically significant improvement in cognitive scores at the highest dose.

Phase III — Large, definitive trials (300–3,000+ patients) that confirm efficacy and monitor rare side effects. Positive Phase III data are typically required for regulatory approval. Example: The Phase III cardiovascular outcome trial demonstrated a 20% reduction in major adverse cardiac events, meeting its primary endpoint.

IND (Investigational New Drug) — An application filed with the FDA before beginning human trials, comprising preclinical pharmacology, toxicology data, and proposed protocols. A cleared IND allows the sponsor to initiate clinical studies. Example: After completing toxicology in rodents, the biotech filed an IND and received clearance within 30 days.

NDA (New Drug Application) — The formal submission requesting FDA approval to market a new small-molecule drug. It integrates all chemical, manufacturing, and clinical evidence. Example: The company submitted an NDA for its hypertension drug and received a PDUFA date ten months later.

BLA (Biologics License Application) — The equivalent of an NDA for biological products such as vaccines, monoclonal antibodies, and gene therapies. It includes data on potency, purity, and stability. Example: The cell therapy candidate’s BLA was accepted with priority review, signaling a faster path to market.

mRNA (messenger RNA) — A single-stranded molecule that conveys genetic instructions from DNA to ribosomes, directing the production of specific proteins. In medicine, synthetic mRNA can be used to trigger an immune response or produce therapeutic proteins. Example: mRNA vaccines encode a viral spike protein, training the immune system to recognize the pathogen.

ADC (Antibody-Drug Conjugate) — A targeted cancer therapy that joins an antibody specific to a tumour antigen with a cytotoxic drug via a chemical linker. The antibody delivers the payload directly to cancer cells, reducing systemic toxicity. Example: Enhertu, an anti‑HER2 ADC, improved overall survival in patients with HER2‑low breast cancer.

Clinical Endpoint — The primary outcome measure used to judge whether a treatment works. Endpoints can be clinical events (survival, heart attack) or surrogate biomarkers (tumor shrinkage, viral load). Example: The trial’s co‑primary endpoints were progression‑free survival and overall response rate.

Double‑blind — A trial design in which neither the participants nor the treating physicians know who receives the experimental therapy or placebo, preserving objectivity. Example: A double‑blind Phase III study prevented biased reporting of side effects that could influence efficacy conclusions.

Orphan Drug — A designation for therapies intended to treat rare diseases (fewer than 200,000 U.S. patients). It provides incentives such as seven‑year market exclusivity, tax credits, and waived FDA fees. Example: A drug for Duchenne muscular dystrophy obtained orphan status, protecting its market even before approval.

Fast Track — An FDA program designed to speed the development and review of drugs for serious conditions with unmet medical needs. It permits more frequent meetings and rolling submission of NDA sections. Example: A pancreatic cancer drug received Fast Track designation, allowing the sponsor to submit completed modules as they became available.

Breakthrough Therapy — A designation for a drug that shows substantial improvement over existing therapies on a clinically significant endpoint. It grants intensive FDA guidance and a commitment to expedited review. Example: The gene therapy earned Breakthrough Therapy status after a small trial showed tumor shrinkage in 80% of patients.

Accelerated Approval — An approval pathway allowing earlier approval based on a surrogate endpoint that is reasonably likely to predict clinical benefit. Confirmatory trials are required to verify the benefit later. Example: A multiple myeloma drug was approved based on response rate, with a post‑market study mandated to confirm improvement in survival.

Patent Cliff — The sharp decline in revenue that occurs when key patents on a blockbuster drug expire, opening the door to generic competition. It is a major risk factor for pharmaceutical investors. Example: Lipitor’s patent cliff erased billions in annual sales for Pfizer within a few quarters.

Cash Runway — The number of months a company can operate before exhausting its cash reserves, assuming no additional financing. It is a crucial metric for pre‑revenue biotech firms. Example: With a $50 million balance and a monthly burn of $4 million, the company’s runway extended to the topline Phase II readout.

Burn Rate — The rate at which a company spends capital, typically expressed as net cash used per month. For clinical‑stage biotechs, it is dominated by R&D and trial costs. Example: The biotech’s burn rate increased to $6 million per month as it enrolled a large Phase III study.

Market Capitalization (Market Cap) — The total market value of a company’s outstanding shares (share price × shares outstanding). For biotech, market cap often reflects the discounted probability‑adjusted value of the pipeline. Example: After positive Phase II data, the market cap swelled from $500 million to $2.2 billion.

Dilution — The reduction in existing shareholders’ ownership percentage when a company issues new equity. It is a common consequence of secondary offerings used by biotechs to raise capital. Example: A $150 million public offering caused 12% dilution but provided the funds needed to complete a pivotal trial.

PDUFA Date (Prescription Drug User Fee Act) — The target date by which the FDA commits to completing its review of a drug application. It is a major catalyst for stock movements. Example: The PDUFA date for the novel anticoagulant was set for May 10, 2026, and a positive outcome would trigger milestone payments.

SPA (Special Protocol Assessment) — A written agreement with the FDA that the design and endpoints of a Phase III trial are acceptable for a regulatory submission. It reduces uncertainty regarding the trial’s validity. Example: The company announced an SPA with the FDA for its pivotal study, boosting confidence that the planned endpoint would support approval.

Royalty (Pharma Licensing) — A recurring payment from a licensee to the licensor, calculated as a percentage of net sales of a commercialized product. It gives the licensor a low‑risk revenue stream. Example: A small biotech earns a 15% royalty on sales of its partnered oncology drug, which generated $80 million in revenue last year.

Licensing Deal — A contractual agreement in which one party (the licensee) obtains rights to develop and market a compound from another (the licensor) in exchange for upfront fees, milestone payments, and royalties. Example: Biogen licensed an Alzheimer’s antibody from a Japanese biotech for $20 million upfront and up to $1 billion in milestones.

Biosimilar — A biologic product that is highly similar to, and has no clinically meaningful differences from, an already approved reference biologic. It is introduced after patent expiry to compete on price. Example: A biosimilar to adalimumab launched at a 30% discount, rapidly capturing market share in Europe.

MAA (Marketing Authorization Application) — The European procedure by which a pharmaceutical company applies for the right to market a drug in the EU. A positive opinion from the CHMP leads to European Commission authorization. Example: After receiving a favorable CHMP opinion, the company’s MAA was granted, allowing launch across Europe.

CAR‑T (Chimeric Antigen Receptor T‑cell therapy) — A personalized cancer treatment in which a patient’s own T cells are genetically engineered to express a receptor that targets malignant cells. It has produced durable responses in certain blood cancers but presents manufacturing challenges. Example: Kymriah became the first CAR‑T therapy approved for pediatric acute lymphoblastic leukemia.

AI in Drug Discovery — The application of machine learning and computational biology to identify targets, design molecules, and predict toxicity. It aims to compress R&D timelines and lower failure rates. Example: Insilico Medicine used AI to advance a fibrosis candidate from target identification to Phase I in under 18 months.

Investor Relations (IR) — The function responsible for communicating a public company’s strategy, financials, and clinical progress to shareholders and analysts. It manages roadshows, earnings calls, and disclosure. Example: The IR team hosted a conference call to explain the unexpected safety signal observed in a Phase II trial.